Miyazaki, Yusuke
Nakano, Kazuhisa
Nakayamada, Shingo
Kubo, Satoshi
Iwata, Shigeru
Hanami, Kentaro
Fukuyo, Shunsuke
Miyagawa, Ippei
Yamaguchi, Ayako
Kawabe, Akio
Saito, Kazuyoshi
Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Article History
Received: 29 November 2020
Accepted: 24 May 2021
First Online: 1 June 2021
Declarations
:
: TSUSBAME is a single-center, single-arm, prospective observational study approved by the ethics review committee of the University of Occupational & Environmental Health, Japan (#H26-200), and informed consent was obtained from all patients.
: Not applicable.
: K. Nakano has received speaking fees from Bristol-Myers, Sanofi, AbbVie, Eisai, Eli Lilly, Chugai, Pfizer, Takeda, and Mitsubishi-Tanabe and research grants from Mitsubishi-Tanabe and Eisai. S. Nakayamada has received speaking fees from Bristol-Myers, UCB, Astellas, Abbvie, Eisai, Pfizer, and Takeda and has received research grants from Mitsubishi-Tanabe, Novartis, and MSD. S. Kubo has received speaking fees from Bristol-Myers. Y. Tanaka has received consulting fees, speaking fees, and/or honoraria from Abbvie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-Myers, Astellas, Eisai, Janssen, Pfizer, Asahi-kasei, Eli Lilly, GlaxoSmithKline, UCB, Teijin, MSD, and Santen and received research grants from Mitsubishi-Tanabe, Takeda, Chugai, Astellas, Eisai, Taisho-Toyama, Kyowa-Kirin, Abbvie, and Bristol-Myers. All other authors declare no competing interests.